SCHEMBL6444797

SCHEMBL6444797

Cc1ccc(-c2nc(N)nc(NCc3ncc(C(F)(F)F)cc3Cl)c2C#N)o1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 1/20 0.40
P2RX2 Q9UBL9 1/20 0.40
ALDH1A1 P00352 8/20 0.37
KDM4E B2RXH2 6/20 0.37
MAPT P10636 5/20 0.37
HPGD P15428 5/20 0.37
MEN1 O00255 5/20 0.37
KMT2A Q03164 5/20 0.37
GAA P10253 4/20 0.37
PKM P14618 4/20 0.37
ALOX12 P18054 3/20 0.37
CASP1 P29466 2/20 0.37
CASP7 P55210 2/20 0.37
HSD17B10 Q99714 2/20 0.37
USP2 O75604 1/20 0.37
ALOX15 P16050 1/20 0.37
ADORA2A P29274 4/20 0.36
KCNH2 Q12809 1/20 0.36
TLR7 Q9NYK1 1/20 0.36
GLA P06280 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6443503 0.86 P2RX3 (0.38) P2RX3P2RX2ALDH1A1KDM4EMAPT
SCHEMBL5041750 0.85 ADORA2A (0.44) P2RX3P2RX2ALDH1A1KDM4EMAPT
SCHEMBL6440567 0.83 ADORA1 (0.46) P2RX3P2RX2KMT2AADORA2AADORA1
SCHEMBL6444686 0.81 RAB9A (0.42) P2RX3P2RX2ALDH1A1KDM4EMAPT
SCHEMBL5040104 0.74 HTT (0.47) ALDH1A1KDM4EMAPTHPGDMEN1
SCHEMBL6442124 0.73 P2RX3 (0.41) P2RX3P2RX2KDM4EMAPTMEN1
SCHEMBL6440886 0.72 PDE10A (0.34) KDM4EMEN1KMT2AHSD17B10ADORA2A
SCHEMBL6441332 0.72 ALDH1A1 (0.44) ALDH1A1KDM4EMAPTHPGDMEN1
SCHEMBL6446153 0.71 ADORA2A (0.38) P2RX3P2RX2ALDH1A1KDM4EHPGD
SCHEMBL6441566 0.69 ADORA2A (0.47) P2RX3P2RX2ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 P2RX3 68/4885P2RX2 58/4885ALDH1A1 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.